Royalty Pharma Announces R&D Funding Collaboration With Biogen
Provided By GlobeNewswire
Last update: Feb 12, 2025
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
Read more at globenewswire.com33.01
-0.27 (-0.81%)
Find more stocks in the Stock Screener
RPRX Latest News and Analysis
2 days ago - ChartmillIs ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Ready to Break Out of Its Range?Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Based on good technical signals, ROYALTY PHARMA PLC- CL A is potentially setting up for a breakout.
